Ingredient or product comparison
[Comparison Table Section]
Conservative management (rest, PT) Reduces mechanical stress, promotes natural healing Red-red: 60–70% success; Red-white: 30–40%; White-white: <5% 6–12 weeks High (multiple RCTs) First-line for small peripheral tears; ineffective for avascular tears Arthrosco
This source-based comparison does not add ratings or recommend a winner.
- Conservative management (rest, PT)
- Reduces mechanical stress, promotes natural healing
- Red-red: 60–70% success; Red-white: 30–40%; White-white: <5%
- 6–12 weeks
- High (multiple RCTs)
- First-line for small peripheral tears; ineffective for avascular tears
- Arthroscopic repair
- Mechanical suture or anchors restore continuity
- Red-red: 85–90% healing; Red-white: 60–75%; White-white: surgical not recommended
- 3–6 months
- High (20+ years surgical data)
- Gold standard for repairable tears in vascular zones
- Meniscectomy (partial removal)
- Removes damaged tissue to eliminate mechanical symptoms
- N/A (tissue removed, not healed)
- Immediate symptom relief
- High
- Reduces pain short-term; accelerates osteoarthritis development long-term
- GHK-Cu peptide therapy
- Stimulates collagen synthesis, reduces inflammation, enhances repair in hypoxic conditions
- Theoretical benefit all zones; no human RCT data
- Unknown (likely 8–16 weeks if effective)
- Low (animal models only)
- Mechanistically plausible for avascular repair; lacks clinical validation
- PRP (platelet-rich plasma)
- Delivers concentrated growth factors to injury site
- Red-red: possible augmentation; White-white: minimal effect
- 8–12 weeks
- Moderate (mixed trial results)
- May enhance surgical repair outcomes; limited standalone efficacy
- Stem cell injection (MSCs)
- Multipotent cells differentiate into chondrocytes
- Under investigation; early data inconclusive
- 12–24 weeks if effective
- Low (Phase I/II trials only)
- Promising but unproven; requires intra-articular delivery